Illumina Aktie News

Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO , Nov. 12, 2025 /PRNews...

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025 Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A ...

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exception...

SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.

Illumina, Inc. ( ILMN ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Conor Noel McNamara - VP of Investor Relations Jacob Thaysen - CEO & Director Ankur Dhingra - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research ...

Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025 GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025 Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025 Repurchased 1.2 million shares of our comm...

Illumina is at a pivotal moment, balancing near-term challenges with innovations in multiomics, AI, and proteomics to redefine its growth trajectory. ILMN's planned SomaLogic acquisition and new AI-driven initiatives like BioInsight strengthen its multiomics strategy and expand high-margin revenue streams. Despite competition and risks from China and regulatory pressures, ILMN maintains strong ...

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellatio...